X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through collaboration, Ono has obtained rights for NM49 from Numab for global development and commercialization, which is a multi-specific antibody designed to activate tumor-associated macrophage phagocytosis for the treatment of cancers.
Lead Product(s): NM49
Therapeutic Area: Oncology Product Name: NM49
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2024
Details:
NM26/NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). MAD data expected to be reported in mid-2024; Single ascending dose (SAD) cohort in healthy volunteers remains ongoing.
Lead Product(s): NM26-2198
Therapeutic Area: Dermatology Product Name: NM26
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).
Lead Product(s): NM26-2198
Therapeutic Area: Dermatology Product Name: NM26-2198
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kaken Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $276.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 31, 2022
Details:
Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules including ND021, emerging from the three multispecific antibody programs based on Numab’s R&D platform and has the licenses to develop and commercialize each of the antibody molecules.
Lead Product(s): ND021
Therapeutic Area: Oncology Product Name: ND021
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Sunshine Guojian Pharmaceutical
Deal Size: $15.2 million Upfront Cash: Undisclosed
Deal Type: Partnership December 14, 2021
Details:
Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.
Lead Product(s): NM21-1480
Therapeutic Area: Oncology Product Name: NM21-1480
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 20, 2021
Details:
Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.
Lead Product(s): NM26-2198
Therapeutic Area: Dermatology Product Name: NM26-2198
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kaken Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2021
Details:
The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA).
Lead Product(s): Multi-specific antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 07, 2020
Details:
With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.
Lead Product(s): ND021
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: 3SBio
Deal Size: $23.8 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
